Tel: 01789 267520

Latest News: Treatments & Research

Charities write to Biogen urging them and NHS England to be Flexible on Price

29 August 2018 / Posted in: Treatments & Research

This is so that, as a matter of urgency, an MAA that merges seamlessly with the current EAP is set up and ensures that all others are also able to access nusinersen at the earliest possible opportunity.

Read full story

Access to Nusinersen Update & How You Can Help

24 August 2018 / Posted in: Treatments & Research

This update recently went out to those on our mailing list. It includes details on the MDUK parliamentary drop-in session that's been organised for 11th September, how you can contact your MP, responding to NICE by 5th Sept, and media involvement.

Read full story

Biogen Announces November Closure of the Expanded Access Programme for Infants Newly Diagnosed with SMA Type 1

23 August 2018 / Posted in: Treatments & Research

We urged Biogen not to take this step which creates yet more immense distress and worry for families. We will continue to focus our advocacy for access to treatment on the urgent need for NICE, NHS England and Biogen to agree the terms of a managed access agreement to replace this EAP ahead of 1 November, as well as the need for a long-term sustainable plan for access.

Read full story

Clinicians and SMA Charities Protest NICE Decision

21 August 2018 / Posted in: Treatments & Research

Clinicians and SMA Charities yesterday expressed the need for urgent action. You can read the letter sent to NICE, NHS England and the National Institute for Health Research, here.

Read full story

Biogen’s Update to the SMA Community Following Publication of NICE’s Consultation Paper

15 August 2018 / Posted in: Treatments & Research

Biogen has provided this community statement in response to yesterday's announcement from NICE.

Read full story

NICE Announcement on Nusinersen

13 August 2018 / Posted in: Treatments & Research

Nusinersen not recommended for funding by NICE is the devastating decision for so many, announced today. One glimmer of hope, however, is that it does leave the door open for a Managed Access Agreement. Comments are needed by 5th September.

Read full story

What Are Your Views On Screening Newborns For SMA?

03 August 2018 / Posted in: Treatments & Research

The National Screening Committee (NSC) has invited us to give comments and feedback on its June 2018 evidence review. Their current recommendation is ‘systematic population screening programme not recommended’. When we submit our response, we would like to represent views from the SMA community about screening newborns for SMA. You can let us know your thoughts and take our survey.

Read full story

Biogen Community Updates re Hydrocephalus

02 August 2018 / Posted in: Treatments & Research

We have received this community update which includes Q and As about the potential risk of hydrocephalus.

Read full story

Roche Community Update Re Risdiplam Development Programme

24 July 2018 / Posted in: Treatments & Research

During the recent Cure SMA researcher meeting in USA, Roche shared progress details of the risdiplam programme which you can read more about here. The update also includes an acknowledgement of the disappointment that UK SUNFISH trial sites were not initiated in time to allow UK patients to take part.

Read full story

EMPoWER: Early Mobility and Powered Wheelchair Evidence Review

05 July 2018 / Posted in: Information, Treatments & Research

We are pleased to be involved with a new project to estimate the costs and benefits of providing young disabled children under 5 years with powered mobility aids

Read full story